Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

iTherX Initiates Phase 1b Study of First-in-Class Hepatitis C Virus Entry Inhibitor ITX-5061

March 15, 2011 By Bio-Medicine.Org

SAN DIEGO, March 15, 2011 /PRNewswire/ — iTherX, a
pharmaceutical company dedicated to discovering and developing a
new class of therapies for hepatitis C, today announced that it has
commenced patient recruitment in an open-label, proof-of-concept
Phase 1b study of its lead compound ITX-5061 in liver transplant
patients with hepatitis C virus infection (HCV).  ITX-5061
represents a first-in-class compound that inhibits entry of the
hepatitis C virus into liver cells.

“ITX-5061 possesses a unique mechanism of action that prevents
the hepatitis C virus from entering liver cells and has
demonstrated potent preclinical antiviral activity against all HCV
genotypes.In addition, it has already demonstrated safety in more
than 280 subjects,” said Jeffrey McKelvy, PhD, MD, President and
Chief Executive Officer of iTherX.  “We hope ITX-5061 will
significantly improve long-term transplant outcomes.”

The primary objective of the Phase 1b clinical trial will be to
assess the safety and tolerability of ITX-5061 in liver transplant
patients.  The study will also assess HCV viral load for three
months after liver transplantation to determine if ITX-5061 has any
immediate and/or sustained impact on viral kinetics in treated
patients. Approximately 20 patients will be enrolled into one of
two cohorts:  one group will receive supportive care only,
while the second cohort will also receive ITX-5061 at a150 mg daily
dose for seven days.  The trial is being conducted at the
University of Birmingham, UK under the direction of David Mutimer,
MBBS, MD, FRACP, FRCP, Reader in Hepatology at Birmingham
University and Consultant Hepatologist to the Birmingham QE
Hospital Liver and Hepatobiliary Unit.

Preclinical studies have shown ITX-5061 to be a potent and
selective inhibitor of HCV entry into hepatocytes, capable of
preventing virus binding/fusion and cell to cell spread, suggesting
ITX-5061  may reduce re-infection rates followi

‘/>”/>

SOURCE

Related Articles Read More >

Engineer inspecting artificial hip joint parts in quality control department in orthopaedic factory
Deburring and finishing for beautiful, functional medical devices
A Medtronic HVAD pump opened up to show the inner workings
FDA designates new Medtronic HVAD pump implant recall as Class I
Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age

DeviceTalks Weekly.

June 24, 2022
How innovative design, commercial strategy is building Cala Trio’s bioelectronic medicine market
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech